ROS-mediated liposomal dexamethasone: a new FA-targeted nanoformulation to combat rheumatoid arthritis via inhibiting iRhom2/TNF-α/BAFF pathways-Reference-Cited by-同舟云学术

ROS-mediated liposomal dexamethasone: a new FA-targeted nanoformulation to combat rheumatoid arthritis via inhibiting iRhom2/TNF-α/BAFF pathways

Published:2021 Issue:47 Volume:13 Page:20170-20185
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Song Yanqin¹²,Ismail Muhammad³,Shan Qi¹,Zhao Jianing¹,Zhu Yanping¹,Zhang Leiming¹,Du Yuan¹,Ling Longbing¹^ORCID

Affiliation:

1. Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education of China), School of Pharmacy, Yantai University, Yantai 264005, China

2. Yantai Center for Food and Drug Control, Yantai 264005, China

3. Henan-Macquarie University Joint Center for Biomedical Innovation, School of Life Science, Henan University, Kaifeng, Henan 475004, China

Abstract

ROS-mediated liposomal dexamethasone with an FA target, termed Dex@FA-ROS-Lips, is fabricated and applied to combat rheumatoid arthritis via inhibiting iRhom2/TNF-α/BAFF pathways.

Funder

Natural Science Foundation of Shandong Province

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2021/NR/D1NR05518F

Reference51 articles.

1. Immunological adaptations in pregnancy that modulate rheumatoid arthritis disease activity

2. Immunometabolism in the development of rheumatoid arthritis